首页 › 基金 › Pivotal bioVenture Partners Investment Advisor LLC › EVMN
Pivotal bioVenture Partners Investment Advisor LLC 对 EVMN 的持仓历史
EVOMMUNE INC · 医疗保健
Pivotal bioVenture Partners Investment Advisor LLC 在 Q3 2026 的 13F 申报中披露持有 EVMN(EVOMMUNE INC)1,926,943 股,市值约 US$15.9M,约占其申报组合的 6.49%,在其申报持仓中市值排名第 5 位。 Pivotal bioVenture Partners Investment Advisor LLC 最近 4 个申报季度中有 4 个季度披露了 EVMN 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-11-14 · 来源: SEC EDGAR Form 13F-HR
Pivotal bioVenture Partners Investment Advisor LLC 对 EVMN 的持仓演变
Pivotal bioVenture Partners Investment Advisor LLC 于 Q4 2025 首次披露 EVMN 持仓:1,926,943 股(约 US$33.0M)。 该持仓在 Q1 2026 达到峰值 1,926,943 股,市值约 US$44.3M。 在 4 次申报中,Pivotal bioVenture Partners Investment Advisor LLC 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 1,926,943 股、市值约 US$15.9M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 1.93M | $32.99M | 新进 |
| Q1 2026 | 1.93M | $44.30M | 持有 |
| Q2 2026 | 1.93M | $25.61M | 持有 |
| Q3 2026 | 1.93M | $15.92M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 EVMN 与 13F 数据
EVMN(EVOMMUNE INC)属于医疗保健行业。我们追踪的基金中还有 105 只申报持有 EVMN,申报仓位最大的包括:RA CAPITAL MANAGEMENT, L.P. (US$46.4M), EQT Fund Management S.a r.l. (US$43.7M), SymBiosis Capital Partners, LLC (US$29.4M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 EVMN 的基金
- RA CAPITAL MANAGEMENT, L.P. 3.49M 股 · $46.44M · Q2 2026
- EQT Fund Management S.a r.l. 5.29M 股 · $43.68M · Q3 2026
- SymBiosis Capital Partners, LLC 1.28M 股 · $29.45M · Q1 2026
- Nan Fung Group Holdings Ltd 1.44M 股 · $11.90M · Q3 2026
- Defilade Capital Management, L.P. 793.14K 股 · $10.54M · Q2 2026
- Velan Capital Investment Management LP 451.25K 股 · $6.00M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 594.03K 股 · $4.91M · Q3 2026
- GREAT POINT PARTNERS LLC 325.00K 股 · $4.32M · Q2 2026
- Avidity Partners Management LP 75.00K 股 · $996.75K · Q2 2026
- NEXTBio Capital Management LP 119.06K 股 · $983.46K · Q3 2026
- Andera Partners 97.36K 股 · $804.21K · Q3 2026
更多关于 Pivotal bioVenture Partners Investment Advisor LLC
常见问题
How long has Pivotal bioVenture Partners Investment Advisor LLC held EVMN?
Pivotal bioVenture Partners Investment Advisor LLC has disclosed EVMN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Pivotal bioVenture Partners Investment Advisor LLC's current position in EVMN?
As of Q3 2026, Pivotal bioVenture Partners Investment Advisor LLC holds 1.93M shares of EVMN (EVOMMUNE INC), valued at $15.92M, representing 6.49% of its reported portfolio and ranking #5.
Has Pivotal bioVenture Partners Investment Advisor LLC been buying or selling EVMN?
In the latest 13F filing (Q3 2026), Pivotal bioVenture Partners Investment Advisor LLC held unchanged its position in EVMN. The position peaked in Q1 2026 at 1.93M shares.
Which other funds hold EVMN?
Other major institutional holders of EVMN include RA CAPITAL MANAGEMENT, L.P., EQT Fund Management S.a r.l., SymBiosis Capital Partners, LLC, among 105 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.